- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adc Therapeutics SA (ADCT)
Adc Therapeutics SA stock price live, this page displays NYSE ADCT stock exchange data. View the ADCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adc Therapeutics SA real time stock price chart below.
What Is the Adc Therapeutics SA Stock Price Today?
The Adc Therapeutics SA stock price today is 0.970.
What Is the Stock Symbol for Adc Therapeutics SA?
The stock symbol for Adc Therapeutics SA is "ADCT."
What Stock Exchange Does Adc Therapeutics SA Trade On?
Adc Therapeutics SA is listed and trades on the NYSE stock exchange.
Is Adc Therapeutics SA a Good Stock to Buy?
Determining whether Adc Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADCT quote. (ISIN: CH0499880968)
What Is the Adc Therapeutics SA Stock Price Today?
The Adc Therapeutics SA stock price today is 0.970.
What Is the Stock Symbol for Adc Therapeutics SA?
The stock symbol for Adc Therapeutics SA is "ADCT."
What Stock Exchange Does Adc Therapeutics SA Trade On?
Adc Therapeutics SA is listed and trades on the NYSE stock exchange.
Is Adc Therapeutics SA a Good Stock to Buy?
Determining whether Adc Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADCT quote. (ISIN: CH0499880968)
0.970
-0.070(-6.72%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.950
1.040
52 wk Range
0.780
4.980
ADCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9501.040
52 wk Range
0.7804.980
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADCT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
3.333
Upside
+243.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.333
(+243.64% Upside)
Adc Therapeutics SA SWOT Analysis
Zynlonta's Challenges | ADC Therapeutics faces market headwinds for its flagship product Zynlonta, with sales falling short of expectations amid fierce competition in DLBCL treatment |
Clinical Pipeline | Explore ADC Therapeutics' ongoing trials, including LOTIS-5 and LOTIS-7, which could potentially expand Zynlonta's indications and market reach |
Growth Prospects | Delve into ADC Therapeutics' strategies for label expansion and combination therapies, which may unlock new market opportunities and bolster Zynlonta's position |
Financial Outlook | Analyst price targets range from $6 to $10 per share, with an $8 target from RBC Capital Markets, reflecting cautious optimism amid market challenges |
Adc Therapeutics SA Earnings Call Summary for Q2/2026
- ADC Therapeutics beat Q2 2026 estimates with adjusted loss of $0.11/share vs. $0.22 expected; revenue hit $19.25M vs. $18.89M forecast.
- Shares fell 3.25% to $1.19 as FDA raised concerns about LOTIS-5 benefit-risk profile despite ZYNLONTA monotherapy remaining unaffected.
- Net product revenue rose 2.8% YoY to $18.6M; restructuring cut 17% of workforce, reducing operating expenses 22% and saving $10M annually.
- Company holds $219.1M cash with runway into 2028; plans FDA breakthrough designation for ZYNLONTA plus glofitamab in 2026.
- Management expects ZYNLONTA growth in 2027 with expansion into earlier-line DLBCL; ASH data presentation planned for year-end 2026.
Last Updated: 2026-08-13, 09:18 a/m
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0.11 / -0.22
Revenue / Forecast
19.25M / 18.89M
Compare ADCT to Peers and Sector
Metrics to compare | ADCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | 8.2x | −0.3x | |
PEG Ratio | −0.02 | −0.25 | 0.00 | |
Price/Book | −0.5x | 2.5x | 2.6x | |
Price / LTM Sales | 1.5x | 80.4x | 3.1x | |
Upside (Analyst Target) | 188.5% | 159.7% | 48.5% | |
Fair Value Upside | Unlock | 14.5% | 6.3% | Unlock |
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound’ and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company’s pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Adc Thera (ADCT) Stock Price Today?
The Adc Thera stock price today is 0.970 USD.
What Stock Exchange Does Adc Thera Trade On?
Adc Thera is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Adc Thera?
The stock symbol for Adc Thera is "ADCT."
What Is the Adc Thera Market Cap?
As of today, Adc Thera market cap is 122.820M USD.
What Is Adc Thera's Earnings Per Share (TTM)?
The Adc Thera EPS (TTM) is -0.650.
When Is the Next Adc Thera Earnings Date?
Adc Thera will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is ADCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Adc Thera Stock Split?
Adc Thera has split 0 times.
How Many Employees Does Adc Thera Have?
Adc Thera has 191 employees.
What is the current trading status of Adc Thera (ADCT)?
As of Aug 20, 2026, Adc Thera (ADCT) is trading at a price of 0.970 USD, with a previous close of 1.040 USD. The stock has fluctuated within a day range of 0.950 USD to 1.040 USD, while its 52-week range spans from 0.780 USD to 4.980 USD.
What Is Adc Thera (ADCT) Price Target According to Analysts?
The average 12-month price target for Adc Thera is 3.333 USD, with a high estimate of 5 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +243.64% Upside potential.
What Is the ADCT Premarket Price?
ADCT's last pre-market stock price is 1.020 USD. The pre-market share volume is 1,350.000, and the stock has decreased by -0.020, or -1.920%.
What Is the ADCT After Hours Price?
ADCT's last after hours stock price is 1.072 USD, the stock has decreased by 0.032, or 3.110%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.